3Sixty Pharma Solutions

Executive Summary

3Sixty Pharma Solutions is a San Diego-based private company founded in 2010, specializing in drug delivery and small molecule therapeutics. With a lean operational model, the company positions itself as a nimble partner for pharmaceutical development, offering experienced support across formulation, preclinical, and early-stage clinical activities. Its expertise in drug delivery technologies enables it to address challenges in bioavailability, stability, and targeted release for small molecule drugs. While the company maintains a low public profile and lacks disclosed financials or pipeline details, its longevity and niche focus suggest a steady role in the contract research and development ecosystem, serving biotech and pharma clients seeking cost-effective, hands-on expertise. Despite limited public information, 3Sixty Pharma is well-positioned to benefit from the growing trend of pharma outsourcing and the increasing complexity of drug delivery. The company's decade-plus track record indicates operational resilience and client trust. However, the absence of disclosed partnerships, funding rounds, or specific milestones constrains visibility. For potential investors or partners, the key appeal lies in the company's specialized capabilities and experienced team. Near-term value creation will likely hinge on securing new development contracts or expanding service offerings, particularly in high-demand areas like long-acting injectables or oral controlled-release formulations.

Upcoming Catalysts (preview)

• Q3 2026Major Service Contract Win with Mid-Size Pharma40% success
• TBDExpansion into New Drug Delivery Technologies (e.g., nanoparticle formulations)50% success
• Q4 2026Strategic Partnership or Joint Venture for Co-Development of Proprietary Delivery Platform25% success